Correlation between erythrocyte aldose reductase level and human diabetic retinopathy

British Journal of Ophthalmology

Volumn 86, Issue 12, 2002, Pages 1363-1366

  Oishi, N ^a   Kubo, E ^a   Takamura, Y ^a   Maekawa, K ^b   Tanimotoy, T ^b   Akagi, Yoshio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ALDEHYDE REDUCTASE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0036895141     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.86.12.1363     Document Type: Article

References (27)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995;113:36-51.
2. Sjoφlie AK, Stephenson J, Aldington S, et al the EURODIAB IDDM Complications Study Group. Retinopathy and vision loss in insulin-dependent diabetes in Europe. Ophthalmology 1997;104:252-60.
3. Akagi Y, Kador PF, Kuwabara T, et al. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 1983;24:1516-19.
4. Akagi Y, Yajima Y, Kador PF, et al. Localization of aldose reductase in the human eye. Diabetes 1984;33:562-6.
5. Kador PF, Akagi Y, Terubayashi H, et al. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1988;106:1099-1102.
6. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990;108:1301-9.
7. Takahashl Y, Wyman M, Ferris F, et al. Diabeteslike preproliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1992;110:1295-302.
8. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neural Neurosurg Psychiatry 1998;64:213-16.
9. Kao YL, Donaghue K, Chan A, et al. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999;48:1338-40.
10. Ogata M, Iwasaki N, Kanamori M, et al. Polymorphism of the aldose reductase gene is associated with aldose reductase protein levels and diabetic microangiopathy. Diabetologia 1997;40:A168.
11. Ko BC, Lam KS, Wat NM, et al. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995;44:727-32.
12. Tanimoto T, Maekawa K, Okada S, et al. Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication. Anal Chim Acta 1998;365:285-92.
13. Kinoshita JH. Cataracts in galactosemia. Invest Ophthalmol 1965;4:786-99.
14. Kinoshita JH. Mechanisms initiating cataract formation. Invest Ophthalmol Vis Sci 1974;13:713-24.
15. Ohashi Y, Matsuda M, Hosotani H, et al. Aldose reductase inhibitor (CT.112) eyedrops for diabetic corneal epitheliopathy. Am J Ophthalmol 1988;105:233-8.
16. Kobayashi T, Kubo E, Takahashi Y, et al. Retinal vessel changes in galactose-fed dogs. Arch Ophthalmol 1998;116:785-9.
17. Nishimura C, Hamada Y, Tachikawa T, et al. Enzyme immunoassay for erythrocyte aldose reductase. Clin Chem 1994;40:889-94.
18. Ito T, Nishimura C, Takahashi Y, et al. The level of erythrocyte aldose reductase: A risk factor for diabetic neuropathy? Diab Res Clin Pract 1997;36:161-7.
19. Takahashi Y, Tachikawa T, Ito T, et al. Erythrocyte aldose reductase protein: A clue to elucidate risk factors for diabetic neuropathies independent of glycemic control. Diab Res Clin Pract 1998;42:101-7.
20. Maeda S, Haneda M, Yasuda H, et al. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes 1999;48:420-2.
21. Ohnishi A, Tanimoto T, Nagaki J, et al. Relationship between erythrocyte aldose reductase level and diabetic complications among 98 NIDDM patients. J Japan Diabet Sac 1996;39:783-8.
22. Nishimura C, Saito T, Ito T, et al. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994;37:328-30.
23. Heesom AE, Hibberd ML, Millward A, et al. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 1997;46:287-91.
24. Chistyakov DA, Turakulov RI, Gorashko NM, et al. Polymorphism of a dinucleotide repeat within the aldose reductase gene in normalcy and insulin-dependent diabetes with vascular complications. Molekul Biol (Moscow) 1997;31:778-83.
25. Neuenschwander H, Takahashi Y, Kador PF. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocular Pharmacol Therap 1997;13:517-28.
26. Robison WG Jr, Laver N. Ocular lesions in animal models of human diabetes. In: Shafrir E, ed. Lessons from Animal Diabetes IV 1993:145-63.
27. Sorbinil Retinopathy Trial Research Group. A randamized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234-44.